These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 26136091)

  • 1. Erratum to: A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance.
    Xu Y; Zhou X; Suehs BT; Hartzema AG; Kahn MG; Moride Y; Sauer BC; Liu Q; Moll K; Pasquale MK; Nair VP; Bate A
    Drug Saf; 2015 Aug; 38(8):767-8. PubMed ID: 26136091
    [No Abstract]   [Full Text] [Related]  

  • 2. A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance.
    Xu Y; Zhou X; Suehs BT; Hartzema AG; Kahn MG; Moride Y; Sauer BC; Liu Q; Moll K; Pasquale MK; Nair VP; Bate A
    Drug Saf; 2015 Aug; 38(8):749-65. PubMed ID: 26055920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design considerations, architecture, and use of the Mini-Sentinel distributed data system.
    Curtis LH; Weiner MG; Boudreau DM; Cooper WO; Daniel GW; Nair VP; Raebel MA; Beaulieu NU; Rosofsky R; Woodworth TS; Brown JS
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():23-31. PubMed ID: 22262590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction.
    Platt R; Carnahan RM; Brown JS; Chrischilles E; Curtis LH; Hennessy S; Nelson JC; Racoosin JA; Robb M; Schneeweiss S; Toh S; Weiner MG
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():1-8. PubMed ID: 22262586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership.
    Stang PE; Ryan PB; Racoosin JA; Overhage JM; Hartzema AG; Reich C; Welebob E; Scarnecchia T; Woodcock J
    Ann Intern Med; 2010 Nov; 153(9):600-6. PubMed ID: 21041580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Creating a Common Data Model for Comparative Effectiveness with the Observational Medical Outcomes Partnership.
    FitzHenry F; Resnic FS; Robbins SL; Denton J; Nookala L; Meeker D; Ohno-Machado L; Matheny ME
    Appl Clin Inform; 2015; 6(3):536-47. PubMed ID: 26448797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mini-Sentinel's systematic reviews of validated methods for identifying health outcomes using administrative and claims data: methods and lessons learned.
    Carnahan RM; Moores KG
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():82-9. PubMed ID: 22262596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Benefits of large healthcare databases for drug risk research].
    Garbe E; Pigeot I
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Aug; 58(8):829-837. PubMed ID: 26092163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re-using Mini-Sentinel data following rapid assessments of potential safety signals via modular analytic programs.
    Toh S; Avorn J; D'Agostino RB; Gurwitz JH; Psaty BM; Rothman KJ; Saag KG; Sturkenboom MC; Vandenbroucke JP; Winterstein AG; Strom BL
    Pharmacoepidemiol Drug Saf; 2013 Oct; 22(10):1036-45. PubMed ID: 23922322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surveillance of Medication Use During Pregnancy in the Mini-Sentinel Program.
    Andrade SE; Toh S; Houstoun M; Mott K; Pitts M; Kieswetter C; Ceresa C; Haffenreffer K; Reichman ME
    Matern Child Health J; 2016 Apr; 20(4):895-903. PubMed ID: 26645616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statistical approaches to group sequential monitoring of postmarket safety surveillance data: current state of the art for use in the Mini-Sentinel pilot.
    Cook AJ; Tiwari RC; Wellman RD; Heckbert SR; Li L; Heagerty P; Marsh T; Nelson JC
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():72-81. PubMed ID: 22262595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preface to supplement. Active surveillance of vaccine safety in the US Food and Drug Administration's Mini-Sentinel program: identification of exposures and outcomes.
    Vaccine; 2013 Dec; 31 Suppl 10():K1. PubMed ID: 24331068
    [No Abstract]   [Full Text] [Related]  

  • 13. Post-licensure rapid immunization safety monitoring program (PRISM) data characterization.
    Baker MA; Nguyen M; Cole DV; Lee GM; Lieu TA
    Vaccine; 2013 Dec; 31 Suppl 10():K98-112. PubMed ID: 24331080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Closing the information gap: informing better medical decisionmaking through the use of post-market safety and comparative effectiveness information.
    Fox B
    Food Drug Law J; 2012; 67(1):83-101, iii. PubMed ID: 24624650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying appropriate reference data models for comparative effectiveness research (CER) studies based on data from clinical information systems.
    Ogunyemi OI; Meeker D; Kim HE; Ashish N; Farzaneh S; Boxwala A
    Med Care; 2013 Aug; 51(8 Suppl 3):S45-52. PubMed ID: 23774519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A policy framework for public health uses of electronic health data.
    McGraw D; Rosati K; Evans B
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():18-22. PubMed ID: 22262589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Food and Drug Administration's Post-Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise.
    Nguyen M; Ball R; Midthun K; Lieu TA
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():291-7. PubMed ID: 22262619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent.
    Fireman B; Toh S; Butler MG; Go AS; Joffe HV; Graham DJ; Nelson JC; Daniel GW; Selby JV
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():282-90. PubMed ID: 22262618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how?
    Trifirò G; Coloma PM; Rijnbeek PR; Romio S; Mosseveld B; Weibel D; Bonhoeffer J; Schuemie M; van der Lei J; Sturkenboom M
    J Intern Med; 2014 Jun; 275(6):551-61. PubMed ID: 24635221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Introduction of U.S. FDA mini-sentinel program].
    Xie YM; Liao X; Shen H
    Zhongguo Zhong Yao Za Zhi; 2013 Mar; 38(5):768-72. PubMed ID: 23724692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.